What is the function of Pitobrutinib? How does it help treat the patient's disease?

Pirtobrutinib (Pirtobrutinib) is a highly selective and reversible Bruton's tyrosine kinase (BTK) inhibitor, mainly used to treat relapsed or refractory patientsB cell malignant tumors, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Its mechanism of action is different from traditional irreversible BTK inhibitors (such as ibrutinib). It can continue to exert anti-tumor effects despite BTK gene mutations or drug resistance. Therefore, it provides a new treatment option for patients who have received BTK inhibitor treatment but are resistant or relapsed.

During the specific treatment process, Pitobrutinib inhibits the BTK signaling pathway and interferes with the B cell receptor (BCR) signaling, thereby inhibiting the growth and proliferation of malignant B cells and inducing their apoptosis. In addition, its reversible combination features allow it to maintain effective treatment while reducing some side effects caused by irreversible inhibition of BTK, such as cardiovascular adverse events and bleeding risks.

Clinical studies have shown that pitobrutinib still has a high response rate for patients who have previously received BTK inhibitor treatment but developed resistance, especially in patients carrying the C481S mutation (leading to resistance to traditional BTK inhibitors). Therefore, pitobrutinib may be an important treatment option for patients who have relapsed despite multiple lines of therapy.

In general, pitobrutinib controls disease progression and improves patient survival prognosis by selectively inhibiting BTK and blocking B malignant signaling pathways. Its high selectivity, reversibility and effectiveness against drug-resistant mutations make it a breakthrough drug in the treatment of B cell malignancies, providing new hope for refractory patients.

Reference materials:https://www.jaypirca.com/